fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Acetaminophen & caffeine & codeine phosphate

2 general benefit · 2 not a benefit

Teva-Lenoltec No.2 · DIN 00653241 · 300 mg & 15 mg & 15 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Teva-Lenoltec No.2 · DIN 00653241 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2018-10-19 · brand TEVA-LENOLTEC NO. 2 · ATC N02AJ06 CODEINE AND PARACETAMOL, N02AJ06 CODEINE AND PARACETAMOL · form Tablet · route Oral · ingredients CAFFEINE 15 MG, CODEINE PHOSPHATE 15 MG, ACETAMINOPHEN 300 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Lenoltec No.2: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0933). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00653241)

Source record
DIN 00653241: Teva-Lenoltec No.2 Raw flags: sec3=Y Item: 280808004; group id 396; item number 0947; lccId None; manufacturer id TEV Source form: Tab; strength: 300mg & 15mg & 15mg Recorded listing: General benefit Source prices (unrounded): $0.0933; ministry $0.0933 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00653241 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6764
Interchangeable products
Tylenol with Codeine No. 2 · DIN 02163934 · not recorded
Shortage status: resolved shortage (ended April 22, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00653241
Shortage record checked October 6, 2026

Teva-Lenoltec No.3 · DIN 00653276 · 300 mg & 15 mg & 30 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Teva-Lenoltec No.3 · DIN 00653276 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2018-10-19 · brand TEVA-LENOLTEC NO. 3 · ATC N02AJ06 CODEINE AND PARACETAMOL, N02AJ06 CODEINE AND PARACETAMOL · form Tablet · route Oral · ingredients CAFFEINE 15 MG, ACETAMINOPHEN 300 MG, CODEINE PHOSPHATE 30 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Lenoltec No.3: Formulary list price $0.10 per unit (the source does not state the unit; exact figure $0.0980). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00653276)

Source record
DIN 00653276: Teva-Lenoltec No.3 Raw flags: sec3=Y Item: 280808005; group id 396; item number 0948; lccId None; manufacturer id TEV Source form: Tab; strength: 300mg & 15mg & 30mg Recorded listing: General benefit Source prices (unrounded): $0.0980; ministry $0.0980 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00653276 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6346
Interchangeable products
Tylenol with Codeine No. 3 · DIN 02163926 · not recorded
Shortage status: resolved shortage (ended December 12, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00653276
Shortage record checked October 6, 2026

Tylenol with Codeine No. 2 · DIN 02163934 · 300 mg & 15 mg & 15 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-09-25 — choose a marketed DIN from the same-category list.Discontinued September 25, 2020 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-09-25 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-09-25 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Tylenol with Codeine No. 2 · DIN 02163934 Manufacturer: Janssen Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2020-09-25 · brand TYLENOL WITH CODEINE NO. 2 - TAB · ATC N02AJ06 CODEINE AND PARACETAMOL, N02AJ06 CODEINE AND PARACETAMOL · form Tablet · route Oral · ingredients CODEINE PHOSPHATE 15 MG, CAFFEINE 15 MG, ACETAMINOPHEN 300 MG · company Janssen inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Tylenol with Codeine No. 2: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02163934)

Source record
DIN 02163934: Tylenol with Codeine No. 2 Raw flags: notABenefit=Y, sec3=Y Item: 280808004; group id 396; item number 0947; lccId None; manufacturer id JAN Source form: Tab; strength: 300mg & 15mg & 15mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02163934 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19248
Interchangeable products
Teva-Lenoltec No.2 · DIN 00653241 · $0.0933
Shortage status: discontinued (September 25, 2020, reported by JANSSEN INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163934
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 25, 2020 — choose a marketed DIN from the same-category list.

Tylenol with Codeine No. 3 · DIN 02163926 · 300 mg & 15 mg & 30 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-09-25 — choose a marketed DIN from the same-category list.Discontinued September 25, 2020 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-09-25 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-09-25 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Tylenol with Codeine No. 3 · DIN 02163926 Manufacturer: Janssen Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2020-09-25 · brand TYLENOL WITH CODEINE NO. 3 - TAB · ATC N02AJ06 CODEINE AND PARACETAMOL, N02AJ06 CODEINE AND PARACETAMOL · form Tablet · route Oral · ingredients CODEINE PHOSPHATE 30 MG, CAFFEINE 15 MG, ACETAMINOPHEN 300 MG · company Janssen inc · schedule Narcotics (cdsa i)
Re-check Health Canada status and shortages (live) · Health Canada product record

Tylenol with Codeine No. 3: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02163926)

Source record
DIN 02163926: Tylenol with Codeine No. 3 Raw flags: notABenefit=Y, sec3=Y Item: 280808005; group id 396; item number 0948; lccId None; manufacturer id JAN Source form: Tab; strength: 300mg & 15mg & 30mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02163926 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19249
Interchangeable products
Teva-Lenoltec No.3 · DIN 00653276 · $0.0980
Shortage status: discontinued (September 25, 2020, reported by JANSSEN INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163926
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since September 25, 2020 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (N02A, N02AJ): coverage varies; not interchangeable

  • Acetaminophen + codeine (PMS-Acetaminophen With Codeine): general benefit, not a benefit
  • Acetaminophen + oxycodone (Teva-Oxycocet): general benefit, not a benefit
  • Acetylsalicylic acid + oxycodone (Ratio-Oxycodan): general benefit, not a benefit
  • Acetaminophen + tramadol (Tramacet): not a benefit
  • Hydromorphone (Hydromorph Contin): general benefit, not a benefit
  • Morphine (M-Eslon): general benefit, not a benefit

4 more in the class list below

Other drugs in the same formulary class (28:08:08 Opiate Agonists) and how they are covered

Matched class: 28:08:08 Opiate Agonists

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Some products covered without a code (check the product listing): ACETAMINOPHEN & CODEINE PHOSPHATE, CODEINE PHOSPHATE, HYDROMORPHONE HCL, METHADONE HCL, MORPHINE SULFATE, OXYCODONE HCL & ACETAMINOPHEN, OXYCODONE HCL & ACETYLSALICYLIC ACID 28:08:08 Opiate Agonists

ACETAMINOPHEN & CODEINE PHOSPHATE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 160mg & 8mg/5mL, 300mg & 30mg, 300mg & 60mg · O/L, Tab

OXYCODONE HCL & ACETAMINOPHEN

· 5 products · General benefit (4), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

OXYCODONE HCL & ACETYLSALICYLIC ACID

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 5mg & 325mg · Tab

TRAMADOL HCL & ACETAMINOPHEN

· 12 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 37.5mg & 325mg · Tab

HYDROMORPHONE HCL

· 28 products · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) · strengths: 4.5mg, 9mg, 3mg, 6mg, 12mg, 18mg, 2mg/mL, 10mg/mL, 1mg/mL, 1mg, 2mg, 4mg, 8mg · CR Cap, Inj Sol-1mL Pk, Oral Sol, Tab

MORPHINE SULFATE

· 35 products · General benefit (31), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 10mg, 15mg, 30mg, 60mg, 100mg, 2mg/mL, 10mg/mL, 15mg/mL, 50mg/mL, 20mg, 50mg, 200mg, 5mg · ER Cap, Inj Sol Amp, Inj Sol-1mL Pk, SR Cap, SR Tab, Tab

FENTANYL TRANSDERMAL SYSTEM

· 22 products · Listed, not a benefit (6), Limited Use, codes 511 (6), Limited Use, codes 689 (2), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 12mcg/hr, 25mcg/hr, 50mcg/hr, 75mcg/hr, 100mcg/hr · Trans Patch

ACETYLSALICYLIC ACID & BUTALBITAL & CAFFEINE & CODEINE PHOSPHATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 330mg & 50mg & 40mg & 15mg, 330mg & 50mg & 40mg & 30mg · Cap

OXYCODONE HCL

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg, 20mg · Tab

TRAMADOL HCL

· 13 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg, 300mg, 50mg · ER Tab, Tab

CODEINE PHOSPHATE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 15mg, 30mg · Tab

METHADONE HCL

· 16 products · General benefit (8), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg/mL, 1mg, 5mg, 10mg, 25mg · Oral Concentrate, Oral Concentrate (Cherry Flavour), Oral Concentrate (Unflavoured), Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:08:08 and 2 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: pain
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. BUTORPHANOL TARTRATE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS Adults BUTORPHANOL Nasal Spray (butorphanol tartrate) is indicated for: • the relief of moderate to severe acute pain. PM: https://pdf.hres.ca/dpd_pm/00069311.PDF; date MAR 24, 2015; DIN 02242504; fetched 2026-09-10 Product monograph CELECOXIB · Limited Use, codes 316, 317 1 INDICATIONS CELEBREX (celecoxib capsules) is indicated for relief of symptoms associated with: • Osteoarthritis, • Adult Rheumatoid Arthritis, and • Ankylosing Spondylitis CELEBREX is also indicated for the short-term ( 7 days) management of moderate to severe acute pain in adults in conditions such as the following: • Musculoskeletal and/or soft tissue trauma including sprains, • Postoperative orthopaedic, and • Pain following dental extraction CELEBREX, particularly at doses higher than 200 mg per day, is associated with an increased risk of serious cardiovascular related adverse events (such as myocardial infarction, stroke or thrombotic events), which can be fatal. PM: https://pdf.hres.ca/dpd_pm/00080998.PDF; date 2025-07-09; DIN 02239941; fetched 2026-09-10 Product monograph CODEINE SULFATE TRIHYDRATE & MONOHYDRATE · Limited Use, codes 201 1 Indications CODEINE CONTIN (codeine controlled release tablets) is indicated for the relief of mild to moderate pain in adults requiring the prolonged use of an opioid analgesic preparation. PM: https://pdf.hres.ca/dpd_pm/00078791.PDF; date 2025-03-04; DIN 02163748; fetched 2026-09-10 Product monograph HYDROMORPHONE HCL · General benefit (21), Listed, not a benefit (3), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (4) 1 INDICATIONS DILAUDID® (HYDROmorphone hydrochloride) is indicated for the relief of moderate to severe pain in adults. 1.1 Pediatrics No data are available to Health Canada. PM: https://pdf.hres.ca/dpd_pm/00072218.PDF; date August 29, 2023; DIN 00125083; fetched 2026-09-10 Product monograph OXYCODONE HCL · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS Supeudol® 5 (oxycodone hydrochloride tablets) / Supeudol® 10 (oxycodone hydrochloride tablets) is indicated for: • relief of moderate to severe pain. PM: https://pdf.hres.ca/dpd_pm/00080231.PDF; date not captured; DIN 00443948; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Adults TEVA-LENOLTEC No. 2 and No. 3 (acetaminophen, caffeine and codeine phosphate) are indicated for the short-term relief of mild to moderate pain. Geriatrics (> 65 years of age) In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, concomitant disease or other drug therapy. Pediatrics (< 18 years of age) There are limited safety and efficacy studies with acetaminophen and codeine in the pediatric population. Therefore, the use of TEVA-LENOLTEC No. 2 and No. 3 are not recommended in patients over 12 and under 18 years of age. Regardless of clinical setting, the use of codeine, including TEVA-LENOLTEC No. 2 and No. 3, is contraindicated in patients below the age of 12 years due to increased safety concerns (see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS, Special Populations, Pediatrics). https://pdf.hres.ca/dpd_pm/00065848.PDF PM date: July 15, 2014 Source product: TEVA-LENOLTEC NO. 2; DIN 00653241; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Tylenol with Codeine No. 2 · DIN 02163934 Shortage status: discontinued (2020-09-25, reported by JANSSEN INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163934

Check this DIN again

Tylenol with Codeine No. 3 · DIN 02163926 Shortage status: discontinued (2020-09-25, reported by JANSSEN INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02163926

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Tylenol with Codeine No. 2, Tylenol with Codeine No. 3: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026